| scholarly article | Q13442814 |
| P2093 | author name string | Hayashi M | |
| Kinoshita M | |||
| Maeda K | |||
| Matsumoto T | |||
| Matsui T | |||
| Wada A | |||
| Fujii M | |||
| Ohnishi M | |||
| Tsutsui T | |||
| Tsutamoto T | |||
| Sawaki M | |||
| Mabuchi N | |||
| P2860 | cites work | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 |
| Captopril in heart failure. A double blind controlled trial | Q36753945 | ||
| Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass | Q36839438 | ||
| Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system | Q37087344 | ||
| Mineralocorticoids, hypertension, and cardiac fibrosis | Q40337147 | ||
| Aldosterone escape during ACE inhibitor therapy in chronic heart failure | Q41016806 | ||
| Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients | Q42547596 | ||
| Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure | Q43492306 | ||
| Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. | Q44835977 | ||
| Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure | Q48093809 | ||
| Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction | Q48469388 | ||
| Brain natriuretic peptide as a cardiac hormone in essential hypertension | Q48571955 | ||
| Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction | Q48657782 | ||
| Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension | Q49168698 | ||
| Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease | Q58812441 | ||
| Biological determinants of aldosterone-induced cardiac fibrosis in rats. | Q64910858 | ||
| Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor | Q67494059 | ||
| Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure | Q69302356 | ||
| Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide | Q71102802 | ||
| ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES) | Q71193550 | ||
| The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction | Q71550904 | ||
| Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart | Q71844423 | ||
| Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis | Q72198058 | ||
| Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone | Q72819723 | ||
| Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations | Q73736775 | ||
| Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure | Q74315512 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| ventricular remodeling | Q7920323 | ||
| spironolactone | Q422188 | ||
| congestive heart failure | Q19000661 | ||
| brain natriuretic peptide | Q66360952 | ||
| P304 | page(s) | 1228-1233 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure | |
| P478 | volume | 37 |
| Q22306358 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q37098407 | A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease |
| Q28258044 | A reappraisal of loop diuretic choice in heart failure patients |
| Q41083010 | ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. |
| Q43818889 | Absolute, not relative, changes are important when interpreting trial data |
| Q58615602 | Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure-A Single Center Experience |
| Q44648728 | Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction |
| Q80232499 | Aldosterone Receptor Blockers in the Treatment of Heart Failure |
| Q46215805 | Aldosterone antagonists: evidence-based yet underutilized effective heart failure therapy |
| Q44075487 | Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway |
| Q37344514 | Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. |
| Q46160863 | Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results |
| Q30619167 | Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy |
| Q96954772 | Approach and Management of Hypertension After Kidney Transplantation |
| Q44956538 | Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. |
| Q93049465 | Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction |
| Q50047461 | Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. |
| Q48237778 | B-type natriuretic peptide in cardiovascular disease |
| Q44213168 | Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy |
| Q82699690 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria |
| Q57689089 | Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction |
| Q37339808 | Biomarkers in heart failure: a clinical review. |
| Q36244209 | Brain natriuretic peptide and optimal management of heart failure |
| Q36440968 | Brain natriuretic peptide levels and left ventricular functional recovery in a chronic heart failure population |
| Q37980254 | Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure |
| Q48259553 | Brain natriuretic peptide: does it play a role in post-cardiac surgery patients? |
| Q30918735 | CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction |
| Q37755067 | Can we use B-type natriuretic peptides to monitor patients with heart failure? |
| Q44983088 | Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. |
| Q27002918 | Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction |
| Q36883558 | Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension |
| Q48442845 | Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. |
| Q48528279 | Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. |
| Q53790696 | Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial. |
| Q48693996 | Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems |
| Q28087715 | Diastolic dysfunction |
| Q47753168 | Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction |
| Q42795421 | Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure |
| Q44323025 | Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy |
| Q48678090 | Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure |
| Q44433581 | Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure |
| Q47689172 | Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure |
| Q48358493 | Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker |
| Q35582571 | Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment |
| Q85342202 | Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms |
| Q48267596 | Elevated BNP with normal systolic function in asymptomatic individuals at-risk for heart failure: a marker of diastolic dysfunction and clinical risk. |
| Q52657397 | Endoplasmic Reticulum Protein TXNDC5 Augments Myocardial Fibrosis by Facilitating Extracellular Matrix Protein Folding and Redox-Sensitive Cardiac Fibroblast Activation. |
| Q38036328 | Eplerenone for the treatment of cardiovascular disorders |
| Q44272913 | Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms |
| Q88711578 | Fluid Management in Patients with Chronic Heart Failure |
| Q35591500 | Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study |
| Q30854596 | High-sensitivity troponin T: a biomarker for diuretic response in decompensated heart failure patients |
| Q46005004 | Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. |
| Q34364927 | Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials |
| Q45981857 | Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. |
| Q44054779 | Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure |
| Q46965426 | Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure |
| Q90404983 | Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges |
| Q38005732 | Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances |
| Q37889518 | Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes |
| Q49954326 | Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives |
| Q37955919 | Mineralocorticoid receptor antagonists for heart failure |
| Q104751425 | Modification of ventriculo-arterial coupling by spironolactone in nonischemic dilated cardiomyopathy |
| Q38815451 | Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications |
| Q48016282 | Myocardial T1 Measurement Predicts Beneficial LV Remodeling After Long-Term Heart Failure Therapy |
| Q40528924 | NT-proBNP and BNP: biomarkers for heart failure management |
| Q44778772 | NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy |
| Q47783590 | NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism. |
| Q48475891 | NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. |
| Q33572286 | Natriuretic Peptide testing in primary care |
| Q51773687 | Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy. |
| Q42832904 | Natriuretic peptides as a prognostic marker and therapeutic target in heart failure |
| Q37638155 | Natriuretic peptides in heart failure: should therapy be guided by BNP levels? |
| Q35015563 | Natriuretic peptides in the diagnosis and management of heart failure |
| Q44532758 | Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine |
| Q48095229 | Pathophysiology of acute heart failure syndrome: a knowledge gap. |
| Q90449914 | Pharmacological and Non-pharmacological Strategies for Volume Overload in Acute Decompensated Congestive Heart Failure: A Review Article |
| Q44653714 | Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats |
| Q48278948 | Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function |
| Q80232497 | Prevention and Reversal of LV Remodeling with Neurohormonal Inhibitors |
| Q41845098 | Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach |
| Q35209084 | RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease |
| Q34462504 | Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas |
| Q34324771 | Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure |
| Q64243768 | SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients |
| Q44558742 | Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). |
| Q46793750 | Spironolactone improves diastolic function in the elderly. |
| Q95273784 | Spironolactone in pulmonary arterial hypertension: results of a cross-over study |
| Q34564309 | Surrogate end points in heart failure |
| Q87844785 | The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study |
| Q64099678 | The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial |
| Q28212913 | The effects of medications on circulating levels of cardiac natriuretic peptides |
| Q35058628 | The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus |
| Q36158063 | The role of aldosterone blockade in patients with heart failure |
| Q35706823 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade |
| Q38063118 | The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure |
| Q57118740 | Timing of Left Ventricular Remodeling in Nonischemic Dilated Cardiomyopathy |
| Q36130511 | Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. |
| Q48475908 | Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state |
| Q43237411 | Update on Renin-Angiotensin-aldosterone blockade in heart failure |
| Q37959158 | Updating the role of natriuretic peptide levels in cardiovascular disease |
| Q24678615 | Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? |
| Q34181625 | Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study. |
| Q36014073 | Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study |
| Q79219448 | Ventricular remodeling in heart failure: a credible surrogate endpoint |
Search more.